Chronische pulmonale Aspergillose

Zusammenfassung

Chronische Verlaufsformen pulmonaler Aspergillosen (CPA) treten bei Patienten unterschiedlicher Disziplinen als seltene Komplikation leichter bis mittelschwerer Immunsuppression oder chronischer Lungenparenchymveränderung auf. Durch unspezifische klinische Ausprägung und protrahierten Verlauf stellen sie für den behandelnden Arzt eine diagnostische und therapeutische Herausforderung dar. Die Diagnosestellung stützt sich im Wesentlichen auf CT-radiologische Kennzeichen und den serologischen Nachweis von Präzipitinen. Therapeutisch sind in variabler Frequenz und Dauer antimykotische Therapien notwendig. Eine Resektion wird lediglich für das simple Aspergillom empfohlen. In den ersten Jahren nach Diagnosestellung ist ein gutes Ansprechen auf antimykotische Therapie beschrieben. Die Langzeitprognose ist ungewiss.

Wir geben einen Überblick über Epidemiologie, Diagnose und Management der CPA. Die Diversität dieses Krankheitsbildes wird durch vier Fallbeispiele illustriert.

Abstract

Chronic pulmonary aspergillosis (CPA) is a rare complication in patients with either mild immunosuppression or various pulmonary diseases. Diagnosis and therapy are challenging because of unspecific symptoms like productive cough, weight loss, fever and haemoptysis. Differential diagnoses are manifold, and CPA is characterized by findings in chest CT and serologic proof of precipitins. Surgery is only recommended for simple aspergillomas. Recurrent prolonged courses of antifungal treatment yield satisfactory short-term outcome, but long-term prognosis is uncertain.

We provide an overview of the literature and present four cases to illustrate disease diversity.

Schlüsselwörter

Chronische pulmonale Aspergillose - chronische nekrotisierende pulmonale Aspergillose - chronische fibrosierende pulmonale Aspergillose - chronische kavitäre pulmonale Aspergillose - kompliziertes Aspergillom - semi-invasive Aspergillose - subakute Aspergillose

Keywords

Chronic cavitary pulmonary aspergillosis - chronic necrotising pulmonary aspergillosis - chronic fibrosing pulmonary aspergillosis - complex aspergilloma - semi-invasive aspergillosis - subacute aspergillosis

• Literatur

• 1 Agarwal R, Vishwanath G, Aggarwal AN et al. Itraconazole in chronic cavitary pulmonary aspergillosis: a randomised controlled trial and systematic review of literature. Mycoses 2013; 56: 559-570
• 2 Al-Shair K, Atherton GT, Harris C et al. Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin infect dis 2013; 57: 828-835
• 3 Baxter CG, Denning DW, Jones AM et al. Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clin Microbiol Infect 2013; 19: E197-204
• 4 Binder RE, Faling LJ, Pugatch RD et al. Chronic necrotizing pulmonary aspergillosis: a discrete clinical entity. Medicine 1982; 61: 109-124
• 5 Cadranel J, Philippe B, Hennequin C et al. Voriconazole for chronic pulmonary aspergillosis: a prospective multicenter trial. Eur J Clin Microbiol 2012; 31: 3231-3239
• 6 Camara B, Reymond E, Saint-Raymond C et al. Characteristics and outcomes of chronic pulmonary aspergillosis: a retrospective analysis of a tertiary hospital registry. Clin Resp J 2014; DOI: 10.1111/crj.12105.
• 7 Denning DW. Chronic forms of pulmonary aspergillosis. Clin Microbiol Infect 2001; 7 (Suppl. 02) 25-31
• 8 Denning DW, Pleuvry A, Cole DC. Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 2011; 89: 864-872
• 9 Denning DW, Riniotis K, Dobrashian R et al. Chronic cavitary and fibrosing pulmonary and pleural aspergillosis: case series, proposed nomenclature change, and review. Clin Infect Dis 2003; 37 (Suppl. 03) S265-280
• 10 Felton TW, Baxter C, Moore CB et al. Efficacy and safety of posaconazole for chronic pulmonary aspergillosis. Clin Infect Dis 2010; 51: 1383-1391
• 11 Fraczek MG, Kirwan MB, Moore CB et al. Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of Aspergillus quantitative PCR. Mycoses 2014; 57: 69-78
• 12 Hope WW, Walsh TJ, Denning DW. The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 2005; 43 (Suppl. 01) S207-238
• 13 Izumikawa K, Tashiro M, Kohno S. Management of chronic pulmonary aspergillosis. Ann New York Acad Sci 2012; 1272: 40-48
• 14 Izumikawa K, Yamamoto Y, Mihara T et al. Bronchoalveolar lavage galactomannan for the diagnosis of chronic pulmonary aspergillosis. Med Mycol 2012; 50: 811-817
• 15 Jhun BW, Jeon K, Eom JS et al. Clinical characteristics and treatment outcomes of chronic pulmonary aspergillosis. Med Mycol 2013; 51: 811-817
• 16 Kohno S, Izumikawa K, Kakeya H et al. Clinical efficacy and safety of micafungin in Japanese patients with chronic pulmonary aspergillosis: a prospective observational study. Med Mycol 2011; 49: 688-693
• 17 Kohno S, Izumikawa K, Ogawa K et al. Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis: a multicenter trial in Japan. J Infect 2010; 61: 410-418
• 18 Kohno S, Izumikawa K, Yoshida M et al. A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Europ J Clin Microbiol Infect Dis 2013; 32: 387-397
• 19 Nakamoto K, Takayanagi N, Kanauchi T et al. Prognostic factors in 194 patients with chronic necrotizing pulmonary aspergillosis. Intern Med (Tokyo, Japan) 2013; 52: 727-734
• 20 Osaki S, Nakanishi Y, Wataya H et al. Prognosis of bronchial artery embolization in the management of hemoptysis. Respiration 2000; 67: 412-416
• 21 Pabst S, Kruger M, Skowasch D et al. Pulmonary aspergillosis: therapeutic management and prognostic factors from 16 years of monocenter experience. Adv Exp Med Biol 2013; 755: 225-236
• 22 Pascual A, Calandra T, Bolay S et al. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-211
• 23 Pena TA, Soubani AO, Samavati L. Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 2011; 189: 167-172
• 24 Regnard JF, Icard P, Nicolosi M et al. Aspergilloma: A series of 89 surgical cases. Ann Thorac Surg 2000; 69: 898-903
• 25 Schweer KE, Bangard C, Hekmat K et al. Chronic pulmonary aspergillosis. Mycoses 2013; DOI: 10.1111/myc.12152.
• 26 Spiess B, Seifarth W, Merker N et al. Development of novel PCR assays to detect azole resistance-mediating mutations of the Aspergillus fumigatus cyp51A gene in primary clinical samples from neutropenic patients. Antimicrob Agents Chemother 2012; 56: 3905-3910
• 27 Strassburg A, Dalhoff K, Engelmann I et al. [Diagnosis of infections in pneumology]. Pneumologie 2010; 64: 474-487
• 28 Uffredi ML, Mangiapan G, Cadranel J et al. Significance of Aspergillus fumigatus isolation from respiratory specimens of nongranulocytopenic patients. Eur J Clin Microbiol Infect Dis 2003; 22: 457-462